Hospital

A study published in JAMA Network Open of opioid-naive patients with acute pain found that opioids were typically used in low doses and for short periods, but pain often lasted longer than expected, and leftover medication was common.

Ennumo is approved for the same indications as its reference product, Neulasta (pegfilgrastim).

These recommendations for acute pulmonary embolism management are most applicable to pharmacists on the interdisciplinary team managing acute PE.

In an interview with Pharmacy Times, Deanna Horner, PharmD, BCPS, discusses how pharmacists can serve as patient advocates in GLP-1 care and how direct access models may simplify the patient journey while preserving clinical oversight.

Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, discusses multimodal analgesia, acute pain pathways, opioid-tolerant patients, suzetrigine, and pharmacist-led interventions across health systems with Pharmacy Times.

A preclinical study demonstrates protective immunity against flu, COVID-19, and RSV without immune interference.

New findings show chronic kidney disease affects the same share of US adults as in 2013, although the disease is increasingly tied to diabetes and heart conditions.

Advances in antibiotic and microbiome-based therapies may reduce recurrence and improve outcomes in patients with recurrent Clostridioides difficile infection. 

The authors said these data support the safety of current coadministration practice.

Danish study links meningioma risk to progestogen contraceptives, including injectable depot medroxyprogesterone acetate and levonorgestrel intrauterine devices.

In an interview with Pharmacy Times, Deanna Horner, PharmD, BCPS, discusses how data, automation, provider-led programs, and pharmacist support can help improve GLP-1 access, appropriate use, adherence, and patient persistence.

In an interview with Pharmacy Times, Matt Christian, director of Supply Chain Insights at USP, discussed the factors driving long-term shortages, the growing role of geographic concentration, and what pharmacists should understand about supply chain resilience.

In addition to the upcoming Annual Forum in September, New England Institute of Ambulatory Care Pharmacists (NEIAP) provides practical education and networking opportunities to support ambulatory care pharmacists.

Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM, discusses the New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum and previews key topics of discussion.

As cannabis evolves, pharmacists must recognize emerging risks from high-potency products, drug interactions, and use-related syndromes to improve patient safety.

Laura Gillespie, PharmD, discusses how her patient-first approach has guided her research collaboration efforts and led to measurable reductions in C difficile infection rates at her institution.

Deanna Horner, PharmD, BCPS, discusses how payers, employers, and health plans can approach GLP-1 coverage by balancing patient access, affordability, clinical value, and long-term cost considerations.

Jennifer Goldman, PharmD, RPh, CDCES, BC-ADM, FCCP, shares the history and mission of NEIAP and explains how the organization provides practical education and networking opportunities.

In addition to explaining how NEIAP has evolved over time, Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM, previews key topics at the upcoming September meeting.

This study validates the need for universal HBV therapy for hepatitis B infections among people coinfected with HIV.

The FDA expanded Casgevy’s indication to include children 2 years and older with sickle cell disease with recurrent VOCs or transfusion-dependent β-thalassemia, making it the first gene therapy approved for patients as young as 2 years with SCD.

By targeting aldosterone synthesis directly, baxdrostat offers a novel mechanism for addressing resistant hypertension.

The systems connecting care are proving just as important as the treatments themselves.

AZA Allsop, MD, PhD, outlines what REMS-style safety monitoring could look like for psychedelic therapies and why top institutions are investing heavily.

Pharmacy Times interviews Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, on how health systems can evaluate suzetrigine for acute pain pathways while balancing evidence, access, formulary sustainability, and pharmacist-led stewardship.

The NIH’s expanded All of Us data set links genomic, clinical, environmental, and wearable data from a diverse population to advance precision medicine and pharmacogenomic research.

Because influenza outbreaks follow a humidity‑temperature curve, climate change may shift flu epidemics and reshape risk from tropics to temperate regions.

A study found worsening chronic kidney disease (CKD) severity was independently associated with increased mortality risk and exponentially higher rates of kidney replacement therapy initiation following ICU admission.